ELAB - Elevai Labs Forward P/S Multiple

Corporate company logo of Elevai Labs Inc. (ELAB)

Elevai Labs Inc. (ELAB) relies on rigorous cold-chain bio-logistics and loyalty within the B2B aesthetic medicine sector. The GURU.Markets portal provides this chart, where the forward P/S ratio demonstrates valuation dynamics, and the 0.50 level represents the current value. Growth prospects are based on the recognition of exosome technologies by cosmetologists and an increase in recurring orders from specialized clinics.

ELAB (elevaiskincare.com) Price-to-Projected Revenue Ratio history from 02/21/2024 to 11/14/2026

Analytical breakdowns for Elevai Labs Inc.

- market price and analyst price targets:
Price Chart Elevai Labs|ELAB - Price Target Chart
- market capitalization statistics:
Market Capitalization Elevai Corp|ELAB - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Elevai Labs|ELAB - Company Book Value|Market Capitalization to Book Value Ratio elevaiskincare.com|ELAB - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Elevai Labs Inc.|ELAB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Elevai Labs Inc.|ELAB - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Elevai Corp|ELAB - Company Long-Term Debt|Company Short-Term Debts Elevai Labs|Quick Ratio elevaiskincare.com
- net income and valuation multiples indicators:
ELAB - Company Net Income|Expected Profit Elevai Labs Inc.|ELAB - Business Payback Period|Projected Price to Earnings Elevai Skincare|ELAB - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Elevai Corp|ELAB - Operating income before deduction of amortization|Earnings per share for the last twelve months Elevai Labs|ELAB - Earnings per share for the last 12 months|Quarterly EPS earnings growth elevaiskincare.com|ELAB - Net earnings per share growth this year|Expected earnings per share growth for next year Elevai Labs Inc.
- sales revenue and business income indicators:
ELAB - Company Gross Revenue|Projected Sales Volume Elevai Labs|ELAB - Price to Sales|Price-to-Projected Revenue Ratio Elevai Corp
Summary company analysis:ELAB (Elevai Labs)
Product sample of elevaiskincare.com

This indicator serves as an asset stress-testing tool, allowing for the determination of the degree of overpayment for future business growth rates. The metric compares the current market value of Elevai Labs Inc. (ELAB) with expected sales volume; therefore, analyzing the projected market cap-to-revenue ratio is critical amid fierce competition with luxury brands capable of eroding the uniqueness of the company's biotechnological formulas.

Who Elevai Labs Inc. competes with

Price-to-Projected Revenue Ratio Krystal Biotech KRYS|Apogee Therapeutics Inc - Price-to-Projected Revenue Ratio|Arcutis Biotherapeutics Inc - Forward P/S Multiple|Market Cap to Future Revenue Ratio Vericel Inc.|ORKA (Oruka Therapeutics Inc) - Forward Price-to-Revenue Multiple|SMTI (Sanara MedTech) - Price-to-Projected Revenue Ratio|DBVT (DBV Tech) - Forward P/S Multiple|Forward P/S Multiple Solesence Inc.|Forward P/S Multiple DERM|Market Cap to Expected Sales Ratio Forte Biosciences Inc|Empro Group Inc - Forward Price-to-Revenue Multiple|Forward Price to Sales SLGL|AXIL - Price-to-Projected Revenue Ratio|MDCX: Price-to-Projected Revenue Ratio|VRCA: Forward P/S Multiple|Hoth Therapeutics (HOTH) - Forward P/S Multiple|BFRI (Biofrontera, Inc.) - Forward P/S Multiple|Price-to-Projected Revenue Ratio VYNE|Price-to-Projected Revenue Ratio Sonoma Pharmaceuticals (SNOA)|Market Cap to Expected Sales Ratio quoinpharma.com|Azitra Corp - Forward Price-to-Revenue Multiple|Forward Price to Sales DRMA|Revance Therapeutics - Forward P/S Multiple